Respiratory Infections

The complex and often frustrating realities that patients face when dealing with a post-infection condition that remains misunderstood by many continue to unfold.

The 2 companies will examine molnupiravir (Lagevrio) using a different formulation that is not approved in any country globally.

A small study shows that 68% of these patients were given this class of medication, which highlights a disconnect between treatment guidelines and clinical practice.

Nirsevimab proves effective in preventing RSV-related medical visits and hospitalizations in infants, with enhanced results in catch-up immunization programs.

Raw milk products are not pasteurized, making them more susceptible to carrying harmful pathogens, in this case, bird flu.

Research finds that individuals who received a COVID-19 vaccine more recently were less likely to develop long COVID.

Mild reactions were experienced in 46% of recipients.

New research using advanced MRI techniques explores how impaired pulmonary gas exchange may contribute to cognitive impairments in Long COVID patients, offering insights for potential treatment strategies.

Recent data shows a 1 in 5 risk of unvaccinated house members transmitting the respiratory virus to other nonimmunized members.

CDPH advises consuming pasteurized milk, which kills the virus, while the state increases testing and monitoring following 29 confirmed human cases of H5N1 linked to infected dairy cows.

Robert H. Hopkins, Jr., MD, medical director, National Foundation for Infectious Diseases (NFID) and ACIP liaison, offers guidance and insights on a variety of respiratory vaccines.

California reports a suspected case of a child; Oregon's first human case linked to a poultry outbreak; and Canada's first locally acquired case in a critically ill teen.

Reactogenicity of mRNA COVID-19 with inactivated influenza vaccine was similar whether given at same time or separated by 1-2 weeks.

Medication errors and patient falls in COVID-19-positive and non-COVID-19 patients highlight the impact of hospital workload on patient safety.

Alveo Technologies announced it entered into an agreement with the Centers for Disease Control and Prevention (CDC) to create a test to help in offering this capability in case there is a need for widespread diagnostics.

Chad Costley, MD, MPH, discussed the platform's ability to respond to emerging respiratory diseases and the challenges in advancing mucosal vaccine development for health preparedness.

Read more about the case of a 71-year-old man who was admitted after presenting with cold-like symptoms for 3 weeks.

Chad Costley, MD, MBA, provided an update on BlueWillow Biologics' NanoVax intranasal vaccine for H5N1, with Phase 1 trial data showing broad immune responses and no serious adverse events.

New therapeutics offer some hope in this emerging market.

Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.

There has been an emergence of extracorporeal membrane oxygenation-associated infections. Here is a review of how to define them and clinical management of this heterogeneous syndrome.

New approach targets multiple strains, promising broad protection against human, avian, and swine influenza viruses.

Clinicians discussed the complexities of diagnosing Long COVID, emphasizing the need for improved biomarkers and diagnostic technologies to better serve affected patients.

The CANOPY Phase 3 clinical trial demonstrated a reduced risk of symptomatic COVID-19, including a 64% reduction during the off-drug follow-up period.

Shionogi’s ensitrelvir demonstrated reduction of symptoms in phase 3 trial.